These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 31960124)

  • 1. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.
    Banna GL; Urzia V; Benanti C; Pitrè A; Lipari H; Di Quattro R; De Giorgi U; Schepisi G; Basso U; Bimbatti D; Rundo F; Libra M; Malatino L
    Support Care Cancer; 2020 Oct; 28(10):4687-4695. PubMed ID: 31960124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
    Caram MEV; Borza T; Min HS; Griggs JJ; Miller DC; Hollenbeck BK; Mukherjee B; Skolarus TA
    J Oncol Pract; 2017 Aug; 13(8):e694-e702. PubMed ID: 28628393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide.
    Riekhof F; Yan Y; Bennett CL; Sanfilippo KM; Carson KR; Chang SH; Georgantopoulos P; Luo S; Govindan S; Cheranda N; Afzal A; Schoen MW
    Clin Genitourin Cancer; 2024 Apr; 22(2):18-26.e3. PubMed ID: 37495480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study.
    Zhang L; Zhou L; Shi Y; An X
    Asian J Surg; 2024 Aug; 47(8):3577-3578. PubMed ID: 38644125
    [No Abstract]   [Full Text] [Related]  

  • 5. Survivin-targeted nanomedicine for increased potency of abiraterone and enzalutamide against prostate cancer.
    Baker A; Syed A; Mohany M; Elgorban AM; Sajid Khan M; Al-Rejaie SS
    Eur J Pharm Biopharm; 2023 Nov; 192():88-111. PubMed ID: 37797680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report.
    Pokrivcak T; Navratil J; Poprach A; Stanik M; Kiss I
    Case Rep Oncol; 2024; 17(1):537-542. PubMed ID: 38577248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model.
    Merdita S; Šíma M; Dvořák J; Matějů M; Richter I; Kozlík P; Křížek T; Královičová J; Bosák J; Petruželka L; Slanař O
    Br J Clin Pharmacol; 2024 Oct; 90(10):2652-2662. PubMed ID: 38958217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial.
    Suttmann H; Gleissner J; Huebner A; Mathes T; Baurecht W; Krützfeldt K; Sweiti H; Feyerabend S
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32911627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Spatial-Temporal Changes in
    Kyriakopoulos CE; Heath EI; Ferrari A; Sperger JM; Singh A; Perlman SB; Roth AR; Perk TG; Modelska K; Porcari A; Duggan W; Lang JM; Jeraj R; Liu G
    J Clin Oncol; 2020 Nov; 38(31):3662-3671. PubMed ID: 32897830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy.
    Banna GL; Di Quattro R; Malatino L; Fornarini G; Addeo A; Maruzzo M; Urzia V; Rundo F; Lipari H; De Giorgi U; Basso U
    Clin Transl Oncol; 2020 Nov; 22(11):2130-2135. PubMed ID: 32232716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
    Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
    Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
    Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
    Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
    J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
    Aggarwal RR; Schweizer MT; Nanus DM; Pantuck AJ; Heath EI; Campeau E; Attwell S; Norek K; Snyder M; Bauman L; Lakhotia S; Feng FY; Small EJ; Abida W; Alumkal JJ
    Clin Cancer Res; 2020 Oct; 26(20):5338-5347. PubMed ID: 32694156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
    Batra JS; Niaz MJ; Whang YE; Sheikh A; Thomas C; Christos P; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
    Urol Oncol; 2020 Nov; 38(11):848.e9-848.e16. PubMed ID: 32600929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.
    Shore ND; Schellhammer PF; Tutrone RF; Mariados NF; Harrelson SS
    Clin Genitourin Cancer; 2020 Oct; 18(5):416-422. PubMed ID: 32475774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.